Ado-trastuzumab Emtansine is used to treat HER2-positive metastatic breast cancer, a specific type of breast cancer that has moved to other parts of the body.

It is used in patients who already received trastuzumab combination with other cancer treating drugs or who showed cancer recurrence. 

None.

IV- The recommended dose is 3.6 mg/kg every 3 weeks (21-day cycle).

It comes as powder for injection (diluted with fluid), to be administered by a healthcare provider into the vein.

• Caution should be exercised in patients with history of liver or heart problem, any allergy, who are taking other medications, elderly, children, during pregnancy and breastfeeding.

• Ado-trastuzumab emtansine should not be administered at doses greater than 3.6 mg/kg.

• Should not substitute for or with trastuzumab.

• Monitor platelet counts prior to each dose of this drug administration.

• Perform HER2 testing while taking this medication.

• Discontinue this medication in patients diagnosed with interstitial lung disease or pneumonitis.

•   Serious Effects : Lung problems, injection site reactions, nerve damage, heart damage, embryo-fetal toxicity.
•   Most Common : Fatigue, nausea, muscle and bone pain, decrease in platelet counts, headache, increased level of liver enzymes and constipation.
•   Miscellaneous : Tiredness, liver problems, nerve problems.

Avoid excess dosage.

Store vials in a refrigerator at 2°C to 8°C.